davita stock symbol Nyse DVA Stock Market Overview

Davita stock symbol is Nyse DVA. It's listed on the New York Stock Exchange.

Davita is a leading provider of kidney care services in the United States.

The company has a strong presence in the dialysis market.

DaVita's valuation metrics are quite impressive. The company's Price/Earnings (Normalized) ratio is 14.49, indicating that investors are willing to pay a premium for its earnings.

Looking at the table below, we can see a comparison of DaVita's valuation metrics with those of its peers.

DaVita's revenue has been steadily increasing, with a 5.56% growth in 2024 compared to the previous year.

DaVita's revenue in 2024 was $12.82 billion, a 5.56% increase from the previous year.

This significant growth is a testament to the company's ability to expand its services and offerings, likely due to its strong presence in the healthcare industry.

DaVita's earnings also saw a substantial boost, increasing by 35.40% to $936.34 million in 2024.

This substantial increase in earnings suggests that the company is not only growing in terms of revenue but also improving its profitability.

Here are the key financial metrics that highlight DaVita's performance:

These metrics provide a snapshot of DaVita's financial health and ability to manage its debt and cash flow.

DaVita's stock price has had its fair share of ups and downs over the years. The current share price is US$142.04, with a 52-week high of US$179.60 and a 52-week low of US$124.42.

The company's beta is 0.93, indicating a relatively stable stock. In the past month, the stock price has decreased by 16.58%, while over the past three months, it has dropped by 15.43%. However, over the past year, the stock price has increased by 13.67%, and over the past five years, it has risen by a significant 72.74%.

Here's a breakdown of DaVita's stock price changes over the past few years:

Note: The 30-year stock price history data only goes up to 1996.

DaVita Inc. has been performing well, but its high debt and current overvaluation have led to a "Hold" rating. Despite this, the company excels in dialysis services and has significant growth potential.

DaVita's financial performance is impressive, with a 5.56% increase in revenue to $12.82 billion in 2024. Earnings also saw a significant jump, rising by 35.40% to $936.34 million.

However, the company's high debt is a concern, which is likely contributing to its overvaluation. DaVita lacks a dividend, which is another factor in the "Hold" rating.

Here's a summary of DaVita's share price performance:

Berkshire Hathaway sold 203,091 shares of DaVita, reducing its stake in the kidney dialysis services provider.

This sale brought Berkshire Hathaway's stake down to about 35.89 million shares.

The current share price of DaVita stock is a whopping $142.04. This is a significant drop from its 52 Week High of $179.60.

The stock has experienced some volatility in the past month, with a 1 Month Change of -16.58%. This is also reflected in its 3 Month Change of -15.43%.

Here's a snapshot of DaVita's stock performance over the past few years:

The stock's beta is a relatively low 0.93, indicating that it tends to move in tandem with the overall market. This might be a reassuring factor for investors looking for stability.

Davita stock symbol, also known as DVA, is a healthcare company that has shown steady growth over the years.

Davita's stock price has fluctuated, but its average return on equity (ROE) has been around 15% in recent years, which is higher than the industry average.

The company's strong financial performance has been driven by its ability to expand its services and increase revenue.

Let's take a closer look at the stock overview for DVA. Trading at 56.2% below its estimated fair value, this stock is a good value compared to its peers and industry.

DVA's valuation score is 5 out of 6, indicating that it's trading at a relatively low price compared to its estimated worth. This is a great opportunity for investors looking to buy at a discount.

The stock's past performance is a strong 4 out of 6, showing that it has a history of delivering solid results. However, its future growth prospects are a concern, with a score of 0 out of 6.

Here's a breakdown of DVA's fundamental analysis scores:

Overall, DVA's stock overview suggests that it's a good value investment opportunity, but investors should be cautious of its uncertain future growth prospects.

As a shareholder, you want to know how your investment in DaVita Inc. (DVA) is performing. Let's take a look at the shareholder returns.

Over the past 7 days, DVA's share price has dropped by 9.8%, which is a significant decline. This is compared to the US Healthcare industry, which saw a 5.8% drop, and the US Market, which only dropped by 2.2%.

Here's a comparison of DVA's returns over the past year:

DVA has actually outperformed the US Healthcare industry, which returned -11.4% over the past year. However, it has underperformed the US Market, which returned 18.3% over the same period.